IL-6 and IL-21 released by CD4+ T cells from NMO patients have been directly linked to neurologic dysfunction [70], and the in vivo level of IL-6 was higher at a 2-year follow-up in relapsed NMO patients [71]. The gene discussed is IL21; the disease is neuromyelitis optica.